Cost-effectiveness of a transvalvular microaxial flow pump in infarct-related cardiogenic shock from the perspective of German statutory health insurance
Year: 2026
Type: article
Abstract: In infarct-related cardiogenic shock, a transvalvular microaxial flow pump reduced 180 day mortality but increased adverse events. We evaluated its cost-effectiveness for German statutory health insurance (SHI). A cohort state-transition model compared the two strategies over a lifetime horizon: a 180 day acute phase from trial outcomes, and chronic states with or without heart failure. Costs and quality-adjusted life-years (QALYs) were discounted at 3% in 2023 euros. Parameter uncertainty was assessed probabilistically and unresolved acute payments by threshold analysis. The pump yielded 1.06 additional QALYs at incremental costs of €38,121 and an incremental cost-effectiveness ratio of €36,083 per QALY. At an illustrative willingness-to-pay threshold of €50,000 per QALY, the probability of cost-effectiveness was 86%. Bleeding 21.8 versus 11.9%, limb ischemia 5.6 versus 1.1%. Due to the lack of arm-specific case-group data, the reference analysis assumed no between-arm difference in acute payments; net monetary benefit (NMB) remained positive below €14,703. Under the reference assumptions, the pump may be cost-effective for German SHI, conditional on an unresolved acute payment difference in which arm-specific routine billing data could be determined. https://www.clinicaltrials.gov identifier: NCT01633502. This economic analysis was not performed separately.
Source: Figshare
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7235999453
